Arterra Bioscience (ARBS) H2 2024 earnings summary

Executive summary

• Production value increased by 6.37% year-over-year to €5.27 million, driven by a 33.7% rise in cosmetic raw material sales.

• Net profit rose 24.21% to €1.34 million, with an EBITDA margin of 32.52% and EBIT margin of 32.3%.

• Financial position remains solid, with a positive net financial position of €5.4 million despite investments.

• Dividend of €0.13 per share proposed, excluding treasury shares.

Financial highlights

• Revenue from sales and services grew to €4.17 million from €3.30 million year-over-year.

• EBITDA reached €1.71 million, up 7.6% from 2023.

• Net income increased to €1.34 million, representing 25.38% of production value.

• Operating costs remained stable, with notable increases in personnel costs (+€122k) and decreases in amortization (-€193k).

• Financial income benefited from higher dividends from Vitalab (€200k vs €160k in 2023).

Outlook and guidance

• Early 2025 data supports optimism for achieving next year's targets.

• Industry growth expected to continue at 9% annually over the next three years.